To combat the nation's
third deadliest cancer, the phase 1b / 2 open - label study will explore the combination of standard chemotherapy and two immunotherapy agents: an anti-PD-1 checkpoint inhibitor and a novel antibody targeting CD40, a protein that when activated can drive the immune system to attack tumors.
Metastatic colorectal cancer,
the third deadliest cancer in the Unites States, is typically treated with two chemotherapy drugs, 5 - Fluorouracil in combination with either oxaliplatin or irinotecan.